Alcohol-attributable cancer deaths in the U.S. doubled from about 11,400 in 1990 to more than 23,100 in 2023.
CME|Podcasts|September 4, 2026
Current Approaches and Future Directions for Early-Stage TNBC
OncLive On Air®
Thanks for your interest in this podcast. Please read this important program information before listening.
Episode Description
In this podcast, experts Nour Abuhadra, MD, and Antonio Giordano, MD, PhD, discuss the emerging role of antibody-drug conjugates (ADCs) in early-stage triple-negative breast cancer (TNBC) and the practice implications of ongoing post-neoadjuvant trials.
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Gilead Sciences, Inc.
Faculty:
Nour Abuhadra, MD
Assistant Professor
Co-Director, Rare Breast Cancer Program, Department of Medicine
Co-Section Head, Triple Negative Breast Cancer Clinical Research Program, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Antonio Giordano, MD, PhD
Assistant Professor, Harvard Medical School
Clinical Director, Center for Cancer Therapeutic Innovation (Early Drug Development)
Medical Director, Breast Cancer Pathway
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
This podcast, including the narration, was produced by the PER® editorial staff based on an online activity conducted with these faculty members. The narration was voiced by a PER staff member or by an AI tool.
To learn more about this topic, including information on datopotamab deruxtecan in the neoadjuvant setting and investigational ADCs on the horizon in early-stage triple-negative breast cancer, go to
Release Date
September 4, 2026
Expiration Date
September 4, 2027
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this activity is for educational purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Related to this article
A donation from Mario Germano Giuliani and Lisa Giuliani will support research in multiple myeloma at Dana-Farber Cancer Institute.
Three new articles from The Lancet Hematology published today examine how clinicians and researchers can better identify, track and measure the effects of blood cancer treatments on patients during treatment and over the long term.
Lab-grown dendritic cells dressed with a sample of a patient’s tumor might someday train the immune system to fight cancer, a study shows.
Richard K. and Nancy K. Lubin have made a $35 million gift to Dana-Farber Cancer Institute’s Future of Cancer Care Fund.
Peter WT Pisters, MD, MHCM, will retire as president of The University of Texas MD Anderson Cancer Center.
MD Anderson Cancer Center recognized outstanding faculty members for their exceptional contributions to cancer research, patient care, prevention, education and leadership.
Mayo Clinic Study Estimates Cancer Risk in Patients With Pancreatic Cysts, Advancing Early Detection
Mayo Clinic researchers have estimated the risk that pancreatic cysts with worrisome or high-risk features will progress to pancreatic cancer or advanced precancerous changes.
Trending on OncLive
1
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
2
Etentamig Meets PFS, ORR Primary End Points in Triple-Class Exposed R/R Myeloma
3
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
4
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
5